Drug preserves visual acuity in patients with choroidal melanoma

Source: Healio, June 2022

Aura Biosciences announced positive visual acuity results from a phase 1b/2 trial of its cancer drug AU-011 in patients with choroidal melanoma.

In the retrospective study, researchers compared data on visual acuity in patients treated with the drug (belzupacap sarotalocan, 43 patients) with data from a previous study on patients who underwent treatment with plaque radiotherapy (150 patients). both groups of patients were at high risk for vision loss and were matched for tumor height, diameter, distance from the fovea and baseline visual acuity.

Among patients in the radiotherapy study, data showed long-term, progressive loss in visual acuity in patients who had tumors close to the fovea.